ABCL

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, 5T4, Translational research, Autoimmunity, Risk, Trichloroethylene, SVP, Cancer, Protein, CD3, Translation, AACR, Doctor of Philosophy, MHC, ABCL, TCE, Safety, CD28, San Diego Convention Center, PSMA, Peptide, Pharmaceutical industry

Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.

Key Points: 
  • Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.
  • “Our data illustrate that we can repeatedly generate TCEs that maximize tumor-cell killing without inducing excessive cytokine release.
  • The data show that AbCellera’s IgG and heavy chain-only CD28-binding antibodies do not display superagonist activity — a property associated with toxicity.
  • “We look forward to advancing these programs with the aim of delivering powerful new medicines for patients.”

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, ABCL

AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

Key Points: 
  • AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
  • A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website .
  • A replay will be available through the same link following the conference call.

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Retrieved on: 
Tuesday, March 19, 2024
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, Conference, ABCL

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, April 16, 2024, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time).

Key Points: 
  • AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, April 16, 2024, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time).
  • A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website .
  • A replay will be available through the same link following the presentation.

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

Retrieved on: 
Monday, March 11, 2024
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, BIIB, SVP, Brain, Doctor of Philosophy, Biogen, Antibody, Neuroscience, ABCL

AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.

Key Points: 
  • AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.
  • “Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience,” said Murray McCutcheon, Ph.D., SVP, Partnering at AbCellera.
  • “We are excited to work with Biogen on this innovative program, which has the potential to unlock multiple new approaches to treating neurological conditions.”
    Under the terms of the agreement, AbCellera will receive an upfront payment and is eligible to receive additional milestone payments should the research programs achieve certain research, developmental and regulatory milestones.
  • AbCellera is also eligible to receive potential royalties on future net sales of products that result from the collaboration.

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, PSMA, San Diego Convention Center, ABCL, AACR, Vaccine

AbCellera will present four posters at AACR that demonstrate how it is leveraging its platform to develop T-cell engagers with potent tumor-cell killing and low cytokine release for multiple cancer targets.

Key Points: 
  • AbCellera will present four posters at AACR that demonstrate how it is leveraging its platform to develop T-cell engagers with potent tumor-cell killing and low cytokine release for multiple cancer targets.
  • Using data integrated from across these programs, AbCellera will present new insights into T-cell engager function.
  • In addition, AbCellera will present data on novel CD28-binding antibodies that can be used to optimize T-cell engagers, particularly for solid tumors that are difficult to treat using current immunotherapies.
  • Details on AbCellera’s poster presentations at AACR are as follows:
    Title: Development of PSMA x CD3 T-cell engagers using an integrated, functional approach

AbCellera Announces Resignation of Board Member

Retrieved on: 
Friday, February 23, 2024
Biotechnology, Pharmaceutical, Health, ABCL, Management

“AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field,” said Peter Thiel.

Key Points: 
  • “AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field,” said Peter Thiel.
  • Effective March 7, 2024, Dr. Andrew Lo, a member of the Company’s Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Directors.
  • “On behalf of the members of our board and management, I express our deep appreciation for Peter’s contributions,” said Carl Hansen, Ph.D., founder and CEO of AbCellera.
  • Effective upon Mr. Thiel’s resignation as a director, the size of the Company’s Board of Directors will be reduced from six to five directors.

AbCellera to Present at Upcoming Investor Conferences in March

Retrieved on: 
Friday, February 23, 2024
Biotechnology, Health Technology, Pharmaceutical, Health, KeyBank, ABCL, Conference, Webcast, Medtech

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:

Key Points: 
  • AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:
    44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time)
    KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time)
    Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website .
  • Replays of each webcast will be available through the same links following the presentations.

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

Retrieved on: 
Tuesday, January 23, 2024
Biotechnology, Pharmaceutical, Health, ABCL

AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

Key Points: 
  • AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
  • A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website.
  • A replay will be available through the same link following the conference call.

AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

Retrieved on: 
Wednesday, December 20, 2023
Biotechnology, Health Technology, Pharmaceutical, Health, Conference, ABCL

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).

Key Points: 
  • AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).
  • A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website .
  • A replay will be available through the same link following the presentation.

AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023

Retrieved on: 
Thursday, November 16, 2023
Biotechnology, Biometrics, Health, Pharmaceutical, Health Technology, ABCL, Conference, Piper Sandler Companies, Nightclub, Broadcasting, AbCellera

AbCellera (Nasdaq: ABCL) today announced that management will present at the Piper Sandler 35th Annual Healthcare Conference in New York, New York on Thursday, November 30, 2023, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).

Key Points: 
  • AbCellera (Nasdaq: ABCL) today announced that management will present at the Piper Sandler 35th Annual Healthcare Conference in New York, New York on Thursday, November 30, 2023, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).
  • A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera’s Investor Relations website .
  • A replay will be available through the same link following the presentation.